Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

新辅助化学疗法在乳腺癌中诱导新拷贝数畸变的出现，并与转移有关

卷 20, 期 9, 2020

页: [681 - 688] 页: 8

弟呕挨: 10.2174/1568009620666200506104523

价格: $65

摘要

背景：在这项研究中，我们检查了新辅助化疗（NAC）之前和之后乳腺癌的CNA遗传状况（CNA –拷贝数畸变），并将肿瘤状况的变化与化疗效率以及无转移生存相关联。 目的：以蒽环类为基础的疗法治疗具有管腔B分子亚型的乳腺癌患者（n = 30）。 方法：为了研究乳腺肿瘤中的CNA，进行了微阵列分析。 结果：确定了NAC对肿瘤CNA景观的三种影响：1-NAC后携带CNA的肿瘤克隆数量减少； 2-NAC后含CNA的克隆数没有变化； 3-用NAC处理增加了带有CNA的克隆的数量（出现了新的克隆）。所有具有新的肿瘤克隆并进行扩增的NAC治疗患者（20％）都有100％形成转移的可能性。在这些情况下，NAC有助于潜在的转移性克隆的出现。我们的研究确定了以下基因座-5p，6p，7q，8q，9p，10p，10q22.1、13q，16p，18Chr和19p-在用NAC处理期间可能被扩增，并可能是潜在的转移性克隆的标记。在其他表现出全部或部分消除了CNA的细胞克隆的患者中，NAC后未观察到新的扩增克隆，且随访5年未发现转移的证据（р= 0.00000）。 结论：我们的数据表明，NAC的主要治疗结果是治疗前消除了肿瘤中潜在的转移性克隆。结果表明有必要采用一种智能的NAC方法来避免转移刺激。

关键词: 克隆进化，乳腺癌，化学疗法，拷贝数异常，转移，CNA遗传环境。

« Previous Next »
图形摘要

[1]
Greaves, M.; Maley, C.C. Clonal evolution in cancer. Nature, 2012, 481(7381), 306-313.
[http://dx.doi.org/10.1038/nature10762] [PMID: 22258609]
[2]
Nik-Zainal, S.; Van Loo, P.; Wedge, D.C.; Alexandrov, L.B.; Greenman, C.D.; Lau, K.W.; Raine, K.; Jones, D.; Marshall, J.; Ramakrishna, M.; Shlien, A.; Cooke, S.L.; Hinton, J.; Menzies, A.; Stebbings, L.A.; Leroy, C.; Jia, M.; Rance, R.; Mudie, L.J.; Gamble, S.J.; Stephens, P.J.; McLaren, S.; Tarpey, P.S.; Papaemmanuil, E.; Davies, H.R.; Varela, I.; McBride, D.J.; Bignell, G.R.; Leung, K.; Butler, A.P.; Teague, J.W.; Martin, S.; Jönsson, G.; Mariani, O.; Boyault, S.; Miron, P.; Fatima, A.; Langerød, A.; Aparicio, S.A.; Tutt, A.; Sieuwerts, A.M.; Borg, Å.; Thomas, G.; Salomon, A.V.; Richardson, A.L.; Børresen-Dale, A.L.; Futreal, P.A.; Stratton, M.R.; Campbell, P.J. The life history of 21 breast cancers. Cell, 2012, 149(5), 994-1007.
[http://dx.doi.org/10.1016/j.cell.2012.04.023] [PMID: 22608083]
[3]
Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N.Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C.R.; Nohadani, M.; Eklund, A.C.; Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P.A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 2012, 366(10), 883-892.
[http://dx.doi.org/10.1056/NEJMoa1113205] [PMID: 22397650]
[4]
Ibragimova, M.K.; Tsyganov, M.M.; Litviakov, N.V. Natural and chemotherapy-induced clonal evolution of tumors. Biochemistry (Mosc.), 2017, 82(4), 413-425.
[http://dx.doi.org/10.1134/S0006297917040022] [PMID: 28371598]
[5]
McGranahan, N.; Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell, 2015, 27(1), 15-26.
[http://dx.doi.org/10.1016/j.ccell.2014.12.001] [PMID: 25584892]
[6]
Devarakonda, S.; Govindan, R. Clonal evolution: Multiregion sequencing of esophageal adenocarcinoma before and after chemotherapy. Cancer Discov., 2015, 5(8), 796-798.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0739] [PMID: 26243860]
[7]
Murugaesu, N.; Wilson, G.A.; Birkbak, N.J.; Watkins, T.; McGranahan, N.; Kumar, S.; Abbassi-Ghadi, N.; Salm, M.; Mitter, R.; Horswell, S.; Rowan, A.; Phillimore, B.; Biggs, J.; Begum, S.; Matthews, N.; Hochhauser, D.; Hanna, G.B.; Swanton, C. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov., 2015, 5(8), 821-831.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0412]] [PMID: 26003801]
[8]
Whiteside, T.L. Immune responses to cancer: are they potential biomarkers of prognosis? Front. Oncol., 2013, 3, 107.
[http://dx.doi.org/10.3389/fonc.2013.00107] [PMID: 23730621]
[9]
Tang, X-R.; Dong, Z.Y.; Wu, D. Prognostic and predictive role of tumor mutation burden and copy number alterations across metastatic cancer: Immunotherapeutic implications. In: AACR; , 2019.
[10]
Zhang, L.; Feizi, N.; Chi, C.; Hu, P. Association analysis of somatic copy number alteration burden with breast cancer survival. Front. Genet., 2018, 9, 421.
[http://dx.doi.org/10.3389/fgene.2018.00421] [PMID: 30337938]
[11]
Abeshouse, A.; Ahn, J.; Akbani, R.; Ally, A.; Amin, S.; Andry, C.D.; Annala, M.; Aprikian, A.; Armenia, J.; Arora, A. The molecular taxonomy of primary prostate cancer. Cell, 2015, 163(4), 1011-1025.
[http://dx.doi.org/10.1016/j.cell.2015.10.025] [PMID: 26544944]
[12]
Li, X.; Xu, W.; Kang, W.; Wong, S.H.; Wang, M.; Zhou, Y.; Fang, X.; Zhang, X.; Yang, H.; Wong, C.H.; To, K.F.; Chan, S.L.; Chan, M.T.V.; Sung, J.J.Y.; Wu, W.K.K.; Yu, J. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics, 2018, 8(6), 1740-1751.
[http://dx.doi.org/10.7150/thno.22010] [PMID: 29556353]
[13]
Cai, H.; Kumar, N.; Baudis, M. arrayMap: A reference resource for genomic copy number imbalances in human malignancies. PLoS One, 2012, 7(5) e36944
[http://dx.doi.org/10.1371/journal.pone.0036944] [PMID: 22629346]
[14]
Iddawela, M.; Rueda, O.; Eremin, J.; Eremin, O.; Cowley, J.; Earl, H.M.; Caldas, C. Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study. BMC Genomics, 2017, 18(1), 526.
[http://dx.doi.org/10.1186/s12864-017-3867-3] [PMID: 28697743]
[15]
Andre, F.; Job, B.; Dessen, P.; Tordai, A.; Michiels, S.; Liedtke, C.; Richon, C.; Yan, K.; Wang, B.; Vassal, G.; Delaloge, S.; Hortobagyi, G.N.; Symmans, W.F.; Lazar, V.; Pusztai, L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res., 2009, 15(2), 441-451.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1791] [PMID: 19147748]
[16]
Zhao, K; Zhao, Y; Zhu, J-Y; Dong, H A panel of genes identified as targets for 8q24. 13-24.3 gain contributing to unfavorable overall survival in patients with hepatocellular carcinoma Curr. Med.Sci., 38(4), 590-596.
[17]
Kutasovic, J.R.; McCart Reed, A.E.; Males, R.; Sim, S.; Saunus, J.M.; Dalley, A.; McEvoy, C.R.; Dedina, L.; Miller, G.; Peyton, S.; Reid, L.; Lal, S.; Niland, C.; Ferguson, K.; Fellowes, A.P.; Al-Ejeh, F.; Lakhani, S.R.; Cummings, M.C.; Simpson, P.T. Breast cancer metastasis to gynaecological organs: A clinico-pathological and molecular profiling study. J. Pathol. Clin. Res., 2019, 5(1), 25-39.
[http://dx.doi.org/10.1002/cjp2.118] [PMID: 30246500]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy